Personalized Treatment Selection and Disease Monitoring Using Circulating Tumor DNA Profiling in Real-World Cancer Patient Management.
Julius WehrleUlrike PhilippMartina JolicMarie FolloSaskia HussungSilvia WaldeckMax DeuterMichael RassnerJan BrauneJustyna RawlukChristine GreilCornelius F WallerHeiko BeckerJesus Duque-AfonsoAnna-L IllertRalph M FritschFrank MeissJustus DuysterNikolas von BubnoffFlorian SchererPublished in: Diagnostics (Basel, Switzerland) (2020)
Collectively, our work highlights the potential of ctDNA assessment by sensitive ddPCR for accurate disease monitoring, robust identification of resistance mutations, and upfront treatment selection in patients with solid tumors. We envision an increasing future role for ctDNA profiling within personalized cancer management in daily clinical routine.